Benjamin MD - LAVA Therapeutics Chief Officer
| LVTX Stock | USD 0.94 0.01 1.08% |
Insider
Benjamin MD is Chief Officer of LAVA Therapeutics NV
| Age | 67 |
| Address | Yalelaan 62, Utrecht, Netherlands, 3584 CM |
| Phone | 31 85 016 3100 |
| Web | https://www.lavatherapeutics.com |
LAVA Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1803) % which means that it has lost $0.1803 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6312) %, meaning that it created substantial loss on money invested by shareholders. LAVA Therapeutics' management efficiency ratios could be used to measure how well LAVA Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2025. Return On Capital Employed is likely to drop to -0.47 in 2025. At this time, LAVA Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 976.9 K in 2025, whereas Total Assets are likely to drop slightly above 96.1 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter MD | Acrivon Therapeutics, Common | 62 | |
| Martin MD | Xilio Development | 63 | |
| Sean Jeffries | Design Therapeutics | 45 | |
| Brian MD | Rezolute | 50 | |
| Joo MD | Design Therapeutics | 61 | |
| Uri MD | Assembly Biosciences | 53 | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Dr IV | Assembly Biosciences | 53 | |
| MD FACP | AN2 Therapeutics | 77 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| MD MBA | Rezolute | N/A | |
| Eric Easom | AN2 Therapeutics | 57 | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Alan Russell | Edgewise Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.18 |
LAVA Therapeutics Leadership Team
Elected by the shareholders, the LAVA Therapeutics' board of directors comprises two types of representatives: LAVA Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LAVA. The board's role is to monitor LAVA Therapeutics' management team and ensure that shareholders' interests are well served. LAVA Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LAVA Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hans MD, Head Innovation | ||
| Wouter Hunnik, VP Resources | ||
| MD MBChB, Chief Officer | ||
| Ton Adang, Chief Officer | ||
| Peter Ros, VP Fin | ||
| Oxana Polyakova, Chief Officer | ||
| Paul Parren, Head VP | ||
| MSc MBA, President CEO | ||
| Fred CPA, Chief Officer | ||
| Benjamin MD, Chief Officer | ||
| Amy JD, General Secretary |
LAVA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LAVA Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (3.82) % | ||||
| Current Valuation | (47.88 M) | ||||
| Shares Outstanding | 26.3 M | ||||
| Shares Owned By Insiders | 36.02 % | ||||
| Shares Owned By Institutions | 35.47 % | ||||
| Number Of Shares Shorted | 30.3 K | ||||
| Price To Earning | 0.54 X | ||||
| Price To Book | 0.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LAVA Stock Analysis
When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.